US Patent 5,362,737 (Aphthous ulcer healing with a specific benzopyranopyridine-3-carboxylic acid): scope, claim boundaries, and US patent landscape
US 5,362,737 claims a topical method for speeding healing of aphthous ulcers by administering a composition containing a specific compound (2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano(2,3-b)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt) in a pharmaceutically acceptable vehicle. Scope is driven by: (1) the specific active-ingredient structure, (2) topical administration to oral mucosa, and (3) clinical endpoint framing (ulcer size reduction as the measure of “speeding healing,” including separation from erythema). The dependent claims add concentration ranges (1% to 5%), treatment duration (three days), enumerated vehicles (e.g., paste, gel, lozenge), specific oral sites, and statistical or clinical significance thresholds.
Because the full patent record is not provided in the prompt, this analysis stays at claim-level and does not identify specific competing patents or assignees.
What is the core scope of US Patent 5,362,737 method-of-treatment claims?
Core independent claim (Claim 1)
A method for speeding healing of aphthous ulcers by reducing ulcer size, using a topical composition applied to oral mucosal membrane comprising:
- 2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano(2,3-b)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt
- in an effective concentration
- in a pharmaceutically acceptable vehicle
Functional definition of the clinical endpoint
- “Speeding the healing … as determined by the reduction of the size of the ulcers.”
- This makes “ulcer size reduction” an essential measurement tied to “healing speed,” not merely symptomatic relief.
Topical route and anatomical limitation
- “Administering topically to the oral mucosal membrane.”
This is a route limitation that distinguishes from systemic therapy. Any infringement analysis turns on whether the accused product delivers the active topically to the oral mucosa and targets aphthous ulcers.
What “consists essentially of” limits in Claim 1?
Claim 1 states the method “consists essentially of reducing the size … by administering … a composition which comprises” the specified active plus vehicle. “Consists essentially of” generally permits additional ingredients that do not materially alter the basic and novel characteristics of the claimed invention. Practically:
- Reformulations with additional standard excipients are likely still within scope.
- Substituting different actives or materially changing the formulation’s essential characteristics would be outside Claim 1.
How do the dependent claims narrow scope: concentration, time, vehicles, site, and statistical endpoints?
Concentration limits (Claims 2–4)
- Claim 2: 1% to 5%
- Claim 3: about 1%
- Claim 4: about 5%
Implication for design-around
- A competitor using the same compound but at concentrations outside 1% to 5% (if truly outside “about” interpretation) can avoid those dependent claims.
- Claim 1 still requires only “effective concentration,” so out-of-range formulations may still implicate Claim 1 unless the effective concentration stays outside Claim 1’s infringement interpretation. In practice, litigation would focus on whether the competitor’s chosen concentration is “effective” for ulcer-size reduction.
Duration (Claim 5)
- Administered for three days
Implication
- This is a hard temporal limitation for Claim 5. Longer or shorter regimens can avoid Claim 5 while still potentially implicating Claims 1–4 and 6–10.
Vehicle enumeration (Claim 6)
Vehicle options listed:
- oral paste
- masticatable gum
- solution
- gel
- disintegrating tablet
- mouthwash
- ointment
- cream
- powder
- aerosolized spray
- lozenge
- troche
- dentifrice
- dental floss
Implication
- This is a broad and “form factor inclusive” list. A topical oral delivery system that fits one of these categories, or arguably fits their functional description, is likely within Claim 6.
- It also makes “pharmaceutical form” an easy infringement hook for product claims built on the same active and use.
Treatment sites (Claim 7)
- buccal mucosa
- oral labial mucosa
- floor of the mouth
- distal half of the tongue
Implication
- The method is limited to these oral sites. A product applied to other intraoral areas could attempt to avoid Claim 7. Claim 1 still requires “oral mucosal membrane,” which is broader than the enumerated sites, so site-specific avoidance may not fully defeat independent claim coverage if the accused therapy is still “oral mucosal membrane” for aphthous ulcers.
Efficacy framing: statistical and clinical significance (Claims 8–9)
- Claim 8: ulcer size reduction is statistically significant
- Claim 9: ulcer size reduction is clinically significant improvement
Implication
- These are evidentiary/threshold limitations. In litigation, they become both a claim construction issue (what defines “statistically” or “clinically”) and a proof issue (trial data, endpoints, statistical methods).
- If the accused product has trial results showing no statistical or clinical significance by the same ulcer-size measurement, that may be used to contest infringement of Claims 8–9.
Endpoint separation from erythema (Claim 10)
- ulcer-size reduction observable separately from reduction of erythema
Implication
- This is an additional mechanistic/measurement requirement. It attempts to avoid collapsing “healing speed” into general anti-inflammatory or analgesic effects that reduce erythema without reducing ulcer size.
- A competitor can attempt design-around by arguing (and proving) that any observed improvements are not separable as ulcer-size changes distinct from erythema changes, depending on how ulcer size and erythema are measured.
What active ingredient scope is covered: exact structure and salts only?
Claim 1 is limited to the compound of the formula:
2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano(2,3-b)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt.
Key scope consequences
- The claims are not written as “substituted” or “analog” coverage. The structure itself is the binding constraint.
- Salts are included, so counterions and salt forms that qualify as “pharmaceutically acceptable” should still fall inside literal scope for the active.
- Ester prodrugs or substantially different derivatives are outside if they are not “the compound” or a “salt thereof.”
How would you expect infringement to be assessed in US for topical oral ulcer healing methods?
Infringement elements tied to claim text
A petitioner/plaintiff would typically frame infringement as satisfying all:
- Aphthous ulcer healing being “sped up” by a reduction in ulcer size.
- Topical administration to oral mucosal membrane.
- Use of the claimed compound or pharmaceutically acceptable salt.
- Formulation includes a pharmaceutically acceptable vehicle.
- For dependent claims: additional constraints (concentration range, vehicle type, location, three-day regimen, statistical/clinical thresholds, and separation from erythema).
How “effective concentration” in Claim 1 works as a boundary
- Claim 1 does not fix concentration. A competitor with the same compound can still infringe Claim 1 if their concentration is “effective.”
- “About 1%” and “about 5%” likely create a narrower band for Claims 3–4 but still depend on evidence and expert interpretation of “about.”
Patent landscape: what other patents are likely implicated by this claim structure?
Given only the claim text and not the patent’s bibliographic record, specification disclosure, assignee, priority, prosecution history, and referenced documents, the landscape can only be described by claim-driven risk categories, not by enumerating specific competing US patents.
High-risk adjacent IP categories for the same therapeutic area
- Topical oral formulations for aphthous ulcers using the same or closely related active
- Many estates in this space cluster around delivery systems (gels, pastes, lozenges) and use endpoints (ulcer size reduction).
- Method-of-use patents for anti-aphthous efficacy measured by ulcer dimensions
- Claim language like “ulcer size” and separation from erythema is common in differentiation around objective endpoints.
- Patents on specific salt forms and formulation concentration ranges
- Dependent claims with 1%–5% ranges suggest the patent holder sought formulation control and may have additional filings around salt variants and excipient systems.
- Preclinical/clinical protocol patents
- Statistical significance and clinically significant improvement claims are often backed by clinical study design. Similar study endpoint patents may exist.
- Combination therapy patents
- “Consists essentially of” in Claim 1 can exclude certain combinations that materially alter the invention’s basic characteristics, but competitors may still pursue combo regimens and attempt to argue outside “consists essentially of.”
What this patent likely protects uniquely
- The combination of:
- a very specific benzopyranopyridine-3-carboxylic acid structure (or salts),
- a topical oral mucosal method,
- the objective endpoint “reduction of ulcer size” used to define “speeding healing,” and
- the ability to observe ulcer-size reduction distinctly from erythema reduction.
That combination is the actionable “claim core” that competitors would need to escape by changing active ingredient, changing route/administration, changing endpoints and measurement, or moving out of dependent constraints.
Claim-scope “escape routes” competitors would typically use (mapped to each limitation)
1) Active ingredient substitution
- Change the active to a different molecule not falling under the exact formula or salt.
- This is the cleanest escape from all method claims because Claim 1 is structurally limited.
2) Route change
- Systemic therapy (oral systemic drugs) likely avoids “topically to the oral mucosal membrane.”
3) Anatomical/administration change
- If a product targets non-enumerated oral sites and the therapy is argued not to be “topically to the oral mucosal membrane” for aphthous ulcers, that can attempt to avoid Claim 7.
- Claim 1 remains broad enough that anatomical arguments can be contested.
4) Regimen design
- Avoid Claim 5 by treating outside “three days.”
- Avoid Claims 2–4 by using concentration outside “about 1%” or “about 5%” and arguing that the chosen concentration is not “effective” for the claimed ulcer-size endpoint under Claim 1’s meaning.
5) Endpoint and measurement strategy
- For Claims 8–10: contest clinical evidence that ulcer-size reduction is statistically and clinically significant and that it is observable separately from erythema reduction.
- Competitors can also structure claims and labeling around analgesia/inflammation reduction rather than ulcer-size reduction as the “healing speed” marker.
What formulations are protected by Claim 6?
Claim 6 is expansive, covering essentially all common topical oral delivery forms: paste, gum, solution, gel, disintegrating tablet, mouthwash, ointment, cream, powder, aerosol spray, lozenge, troche, dentifrice, and dental floss.
Practical effect
- A formulation using the claimed active and dosed for aphthous ulcers in any of these forms is more likely to fall into Claim 6, leaving fewer design-around options based on dosage form alone.
What does Claim 10 imply for clinical trial endpoint selection?
Claim 10 adds an endpoint relationship constraint:
- ulcer-size reduction must be observable separately from erythema reduction.
Implication for evidentiary record
- Trials that measure both ulcer dimensions and erythema and report separable effects are better positioned to support infringement of Claim 10.
- Trials showing only erythema reduction without clear ulcer-size reduction separable from erythema are better positioned to contest Claim 10.
Key takeaways
- Claim 1 is the central hook: topical oral mucosal administration of a specific benzopyranopyridine-3-carboxylic acid (or salt) to speed aphthous ulcer healing measured by reduction in ulcer size.
- Dependent claims create layered constraints on concentration (1%–5%), duration (three days), dosage form/vehicle list, oral sites, statistical and clinical significance, and separation from erythema effects.
- Best design-around is active substitution; route change and endpoint reframing can also reduce risk but typically require both formulation and evidence alignment.
- Form factors are broadly covered under Claim 6, making delivery form a weaker escape route than active or clinical endpoint.
FAQs
1) Does US 5,362,737 cover systemic treatment of aphthous ulcers?
No, the method claims require topical administration to the oral mucosal membrane.
2) Can a competitor avoid Claims 2–4 by using a concentration below 1% or above 5%?
Claims 2–4 are concentration-limited. That can avoid those dependent claims, but Claim 1 may still apply if the concentration is “effective” for ulcer-size reduction.
3) Are gels, lozenges, and mouthwashes covered?
Yes. Claim 6 lists gel, lozenge, mouthwash, and other common oral topical delivery vehicles.
4) What does “clinically significant improvement” add to Claim 9?
It adds a clinical threshold requirement on ulcer-size reduction, making infringement dependent on clinical evidence and how “clinical significance” is established.
5) Is erythema reduction alone sufficient to meet the claims?
No. Claim 10 requires ulcer-size reduction observable separately from erythema reduction, and Claim 1 ties “speeding healing” to ulcer-size reduction.
References
(No sources cited. The prompt provided only the asserted claims, not bibliographic or patent-record information needed to cite primary documents in APA format.)
